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Fatty acid transport proteins (FATPs) provide pivotal roles in fatty acid
transport and activation and thus are crucial for overall fatty acid
homeostasis. Peroxisome Proliferators Activated Receptors (PPARs) are
important transcription factors, which control many genes that govern lipid
metabolism.
Using 293 T-REx cell lines that stably express FATP1 or FATP4 from a
tetracycline-inducible (Tet) promoter, this work evaluated gene expression
of key genes involved in fatty acid metabolism using quantitative
polymerase chain reaction (Q-PCR), protein expression of FATP1 and
FATP4 using Western blots, and fatty acid transport to address the roles of
these two FATP isoforms in fatty acid homeostasis. This work found that the
expression of FATP1 from the heterologous Tet promoter resulted in

increased FATP4 expression from its native promoter; the expression of
FATP4 from the Tet promoter did not, however, increase the expression of
FATP1. These results identified an unexpected regulatory loop between
FATP1 and FATP4, which is hypothesized to occur at the transcriptional or
post transcriptional level. Western blots confirmed these relationships by
evaluating the protein expression of FATP1 and FATP4. Studies monitoring
the transport of fatty acids using the fluorescent long chain fatty acid C1BODIPY-C12 demonstrated the expression of FATP1 resulted in higher
levels of transport relative to FATP4 overexpression. To address whether
this regulatory loop proceeds through PPARa or PPARg, the expression of
these two genes along with PPARs target genes were monitored. The over
expression of FATP1 and FATP4 from the Tet promoter did not increase
PPARs gene expression; the expression of FATP1 from the Tet promoter did
result in an increased expression of PPARa target genes. Collectively these
results supported the conclusion that the enzymatic product of FATP1
resulted in increased expression of FATP4 through a PPARα-mediated
process. To further address this question, fatty acid and fatty acyl CoA
profiles were measured in 293 T-REx cells expressing FATP1 or FATP4.
The acyl CoA profiles showed both C18:2-CoA and C20:4-CoA were

elevated in FATP1 expressing cell lines, perhaps indicating a relationship in
n-3 fatty acid activation including further downstream metabolism. Likely
effectors in this regulatory loop are arachidonic acid metabolites, including
prostaglandins.
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Chapter 1. Introduction

I. Significance
Long chain fatty acids (LCFAs) are important molecules for our life. They
are important components in the storage and generation of energy, and also
contribute to many essential cellular processes (1).

Different research studies indicate that LCFAs function as hormone-like
components (2, 3, and 4). For example, they can affect gene expression and
function as effectors by activating nuclear receptors including PPAR family
members and can initiate the release of insulin through G-protein-coupled
receptor (GPCR) (5, 6). LCFAs are also involved in the innate immune
response by modulating toll-like receptor (TLR) signaling (7, 8 and 9). The
chronic imbalances in lipid metabolism can give rise to many different kinds
of health disorders including nonalcoholic fatty liver disease, obesity, cancer,
Type II diabetes, heart disease, and hyperlipidemia. From a fundamental
standpoint, LCFAs have a profound physiological significance. (10, 11, 12,
13)

2

To assert their diverse effects, LCFAs must first be transported across the
plasma membrane. Evidence shows that LCFAs traverse the membrane
using several distinct mechanisms. The uptake of LCFAs is likely proteinmediated via fatty acid transport proteins (FATP), fatty acid translocase
(FAT/CD36) and/or fatty acid binding proteins (FABP) (14, 15, 16, 17 and
18).

There is a significant body of work that has been done establishing these
proteins in the process of fatty acid uptake. An additional level of
complexity comes from studies showing the expressions of FATP,
FAT/CD6, and FABP proteins are controlled at multiple levels including
transcription and post-transcription (19, 20). Because of these controls, the
lipid balance inside of the cells is very tightly regulated (21).
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II. Fatty acid transport proteins (FATPs)

Of the proteins implicated in fatty acid uptake, the fatty acid transport
proteins (FATPs) represent an important group. In humans, there are six
FATP members: hsFATP1 to hsFATP6. Each of these proteins is expressed
in the tissues or cells which utilize fatty acids and/or have high levels of
lipid metabolism. FATP1 and 4 are the most predominant FATPs in
mammalian cells (22, 23). Fatty acid transport proteins function in fatty acid
uptake by working independently or coordinately with a long chain acylCoA synthetase; in both cases fatty acid transport and activation represent a
coupled process referred to vectorial acylation.

FATP1 is the predominant FATP in adipose tissue and muscle. It is quite
important for energy homeostasis, thermogenesis and insulin resistance (24).
When FATP1 is knocked out in mice, they do not show any signs of insulin
resistance when they are fed a high fat diet. Under pathological conditions,
FATP1-mediated fatty acid uptake may result in the accumulation of neutral
lipid intramuscularly, which has been linked to insulin resistance (25).
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FATP4 knockout mice are lethal; evidence to date suggests they cannot form
a normal embryo. To date, there is no evidence linking FATP4 to insulin
resistance (26). FATP4 is over expressed in human adipose tissue in obese
individuals. Tissue specific deletion of FATP4 in the skin results in a
phenotype of skin homeostasis failure, which is likely linked to the
formation of skin waxes (27). Studies of different FATPs show their unique
and crucial roles in the epidermis for maintaining skin barrier and
keratinocyte homeostasis. Animal models of FATP4 deficiency, as well as
human phenotype in IPS, have demonstrated a vital role for FATP4 in
mammalian skin development and formation of epithelial barrier, which may
be due to its very long chain acyl-coenzyme A synthetase activity.
Pathomechanism of FATP4 deficiency in skin is still poorly understood and
clarifying of specific pathways affected by such deficiency may yield new
insights for the role of fatty acid metabolism in epidermal biology.

FATP5 knockout mice have abnormal hepatic fatty acid uptake and bile
acid reconjugation. These data suggest that FATP5 is a bifunctional protein
both at the level of fatty acid uptake, but also in bile acid activation and
reconjugation (28).

5

Indeed most fatty acid transport proteins are increasingly being recognized
as multifunctional proteins that mediate the uptake of fatty acids and
catalyze the formation of coenzyme A derivatives using long-chain fatty
acids, very-long chain fatty acids, and bile acids. The enzymatic product for
most FATPs is likely to be a fatty acyl CoA that may function as an effector
of different metabolic pathways. The interrelationships between the different
isoforms of FATPs in the context of fatty acid metabolism have not been
studied (29, 30).

Modulation of fatty acid transport protein function can result in altered
energy homeostasis and insulin sensitivity, defective skin homeostasis, and
altered bile acid metabolism. Both fatty acid uptake and enzymatic activity
of fatty acid transport proteins likely contribute to these phenotypes. Future
studies are needed to better understand the molecular mechanism of fatty
acid transport protein function and the physiological role of FATP2, FATP3,
and FATP6.
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III. Peroxisome proliferator-activated receptors (PPARs)

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear
receptor superfamily, of which there are three subtypes: PPAR alpha, PPAR
beta (or delta) and PPAR gamma. (31)

Fibrates and fatty acids are peroxisome proliferators which can activate the
transcriptional activity of these receptors. Prostaglandin derivatives are the
only natural ligands of PPAR gamma. PPAR have been identified as an
antidiabetic molecule by binding thiazolidinedione with high affinity (32).
After binding with the activating ligands, PPARs form heterodimers with
retinoic X receptor (RXR) and translocate into the nucleus where they alter
the transcription level of its target genes through binding Peroxisome
Proliferator Response Elements (PPREs). PPRE is a simple repeat of the
hexameric DNA recognition motif (XGGTCA) spaced by 1 nucleotide (33).
Natural fatty acids and drugs are often used to activate PPARs and affect
lipid metabolism. Each PPAR isotype is preferentially activated by specific
ligands. For example, leukotriene B4 activates all isotypes, but it activates
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PPARα preferentially. (42) PPARα is also activated by arachidonic acid
(AA) and fibrates, which links this nuclear factor to atherosclerosis. (43)

PPARs regulate the expression of target genes, which are implicated in
cellular lipid metabolism. Our current understanding of PPARs show they
can be considered as multiple function factors because their activation can
trigger adipocyte differentiation and other genes crucial to adipogenesis (34).
This suggests the PPARs are involved in the regulation of the immune
system, maintain nutrient balance and lipid metabolism, and regulate the
transcription of key genes involved in lipid metabolism. At present, there are
reports showing the enzymatic products of one or more of the FATPs
activate the different PPAR subtypes.

PPARα are expressed mainly in the liver, heart, skeletal muscle, kidney and
small intestine. They are present in important mechanisms, such as the
capture and oxidation of fatty acids; synthesis of ketone bodies; metabolism
of apolipoproteins (apoAI and apoAII); expression of genes involved in
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gluconeogenesis; inhibition of transamination and deamination of amino
acids, as well as the blocking of urea synthesis. (39)

PPARβ/γ is widely distributed in the tissues and is expressed in the placenta
and small intestine. The mechanisms involving the gene expression
regulation of this receptor are unknown, but it is an important agonist in the
treatment of dyslipidemia and cancer and acts in the differentiation of central
nervous system cells. (38, 40)

PPARγ is abundant in adipose tissue and is present in low concentrations in
the skeletal muscle of humans. As a receptor of antidiabetic drugs
(troglitazone and rosiglitazone), it leads to increased sensitivity to insulin in
the adipose and muscle tissues, by improving glucose metabolism; reduces
inflammation and promotes the differentiation of pre-adipocytes in
adipocytes. (41)
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IV. Previous Work

For defining the roles of the different isoforms of fatty acid transporter
proteins in fatty acid trafficking precisely, all six murine isoforms were
expressed and characterized in a genetically modified yeast strain. This
strain cannot transport long-chain fatty acids and has deficient long-chain
acyl-CoA synthetase activity. Murine FATP1, FATP2 and FATP4 rescued
the mutation in fatty acid transport and very long-chain fatty acid
esterification associated with a remove of the yeast FAT1 gene; but three of
these 6 isoforms: FATP3, FATP5 and FATP6 did not complement the
transporter function even though all of them were localized in the yeast
plasma membrane (35).

FATP1 was the predominant isoform located in adipocytes consistent with
the function in the transportation and activation of exogenetic fatty acids
destined for storage of triglycerides. In intestinal-like Caco-2cells and liverlike HepG2 cells, in which there were lots of fatty acid processing, FATP2
was the predominant isoform in these two cell lines(36).
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Dr. Melton did some important research work on FATP2 in our lab. Two
splice variants of human FATP2: FATP2a and FATP2b were identified and
shown to have distinguishing metabolic characteristic suggesting differential
functions in fatty acid homeostasis. Dr. Melton overexpressed FATP2a and
FATP2b in yeast or 293 T-REx cells. Both of them were sufficient for long
chain fatty acid import. However, only the full length variant FATP2a
performed very long chain acyl-CoA synthetase activity (37).

Our lab is also investigating main fatty acid transport proteins in human.
And the coding sequences for FATP1 and FATP4 were amplified by PCR
using suitable generating double restriction enzyme cut sites respectively
and cloned into pcDNA4/TO/myc-His (Invitrogen) and propagated in an
Escherichia coli strain; the sequences of both expression clones were
verified. Stable cell lines expressing human FATP1 and FATP4 were
generated by transfection of the constructs into stable 293T-REx cell lines
(InVitrogen; stably expressing the tetracycline repressor protein) by Dr. Elsa
Arias-Barrau. Western blot has been done by her using multiclonal antibody
of human FATP1 and FATP4. And the band for FATP1 only exist in FATP1
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over expression cell line sample, but the band for FATP4 exist in both
FATP1 and FATP4 over expression cell lines samples.
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V. Hypothesis
The expression of human FATP1 increases the expression of human FTAP4
through a mechanism involving PPARα and not PPARγ. This regulation of
FATP4 by FATP1 may be mediated by the enzymatic product of FATP1,
which may activate PPARα post-translationally.

13

Chapter 2. Materials and Methods

I. Cell Culture

293T-REx stable cell lines allowing the controlled expression of FATP1 and
FATP4 were established by Elsa Arias-Barraua with the vector pcDNA4 /
TO / myc-His (Invitrogen) and were seeded at 5x103 cells/cm2 in T75 flasks
in DMEM medium containing 10% FBS, 5µg/ml blasticidin and125µg/ml of
zeocin to keep and expand the cell lines. The selective medium was replaced
every 3-4 days. When cells were more than 90% confluent they were split
1:3 into new T25, T75, and T150 flasks. Induction of expression of FATP1
or FATP4 was accomplished by the addition of tetracycline to a final
concentration of 2µg/ml for 48h; the cells were harvested and then subjected
to analytical studies as detailed below.
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II. Time-course fatty acid uptake assay

The ability of fatty acid transport was monitored using the live-cell, realtime method and the fluorescently labeled fatty acid, 4, 4-difluoro-5-methyl4-bora-3a, 4adiaza-s-indacene-3-dodecanoic acid, C1-BODIPY-C12, in
combination with the quenching agent trypan blue. To monitor fatty acid
transport, the stable 293 T-REx cell lines grown under standard conditions in
the presence of tetracycline (2µg/ml) (see above) in optically transparent 96
well plates. Cells were seeded at 50,000 cells per 96 well in standard media
containing 5µg/ml Blasticidin and 125 µg/ml Zeocin. 24h after plating
2µg/ml of tetracycline was added to the cells for induction. 48h post
induction cells were serum-starved for 1h in MEM prior to performing the
C1-BODIPY-C12 transport assay. Subsequently 50µL of the C1- BODIPYC12 mixture in different final concentration of BODIPY: 1 µM, 5 µM, 10
µM, 20 µM and 40 µM (For 5 µM final concentration of BODIPY: 10µM
C1-BODIPY-C12, 10µM BSA, 4mM trypan blue) was added to each well.
Transport was determined immediately by measuring the cell associated
fluorescence, which was measured using a Bio-Tek Synergy HT
multidetection microplate reader (Bio-Tek Instruments, Inc. Winooski, VT)
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using filter sets of 485 nm ± 20 excitation and 528 nm ± 20 emission. Data
were collected as arbitrary fluorescence units (AFU)/3 x 106 cells/30sec. The
cell number in each well was determined using a standard Hoechst assay
used to quantify DNA. The fluorescence was read at 350nm/450nm
(excitation/emission). The cell number was calculated from a standard curve
generated for cell number verses fluorescence units. Data analysis is done
with PRISM software. (n=3)
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III. Western Blot

The expression of FATP1 and FATP4 were monitored by western blot
analysis using FATP1 and FATP4 monoclonal antibodies (Invitrogen)
coupled with the appropriate secondary antibodies. After 48 h Tet induction,
the 293 T-Rex cells were harvested. The cell pellets of FATP1
overexpression, FATP4 overexpression and empty cell lines were
resuspended. Cells were sonicated for 150 sec (3 sec on, 5 sec off), 20% amp.
Then, cells were centrifuged at 13200 rpm for 15min, 4 °C. Supernatants
were transfered to a new tube. The protein concentrations were tested using
a plate reader: 200ul 1:4 diluted protein assay reagent (from Bio-Rad) + 1 ul
my sample or + 10 ul standard BSA. Then a 12% Poly Acrylamide Gel
Electrophoresis was performed. Gel was run at 80V (constant) through the
stacker and 120V (constant) through the running gel. Then, the semi-dry
transfer was performed using 0.4 amps constant and run for 30 minutes. The
membrane was wet in PBS for several minutes. Then, the first antibody is
used in 1:3000 dilution and 1:15000 in Li-Cor western buffer for second
antibody for the blot. The membrane is scanned by membrane scanner.
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IV. LC- /MS/MS Analysis of Fatty Acyl CoA Pool

Cells were grown to confluence in T75 flask and harvested in PBS. Cell
pellet was gently washed with 5 ml PBS and placed on ice immediately.
Cells were resuspend in 0.5 ml water and mixed up and down several times
with pellet tip to get uniform suspension. 50ul of all was used for cell
counting and protein concentration determination. 200ul aliquot of this
suspension was pipetted out into a screw cap tube on ice. 500ul of methanol
containing 1mM EDTA was added to the aliquot. Then, the mixture was
sonicated for 30 seconds. 10ul of internal standard (C17:0 CoA, C19:0 CoA,
C23:0 CoA) was added. 250ul chloroform was added at last. The mixture
was sonicated for 30 seconds and incubated at 50 ºC for 30 minutes in a
heating block or water bath. After this, the mixture was cooled to room
temperature. 250ul water was added to it, and the mixture was vortexed and
mixed. The mix was centrifuged to get pellet at 3000 rpm, 5 min, 25 ºC. The
upper phase was removed with pipette to a new screw cap tube. The
remainder

was

re-extracted

twice

each

time

with

500ul

(H2O/CH3OH/CHCl3-45/50/5) followed by centrifuge (3000 rpm, 5 min, 25
ºC). The upper phase was collected and combined to the first extract. 180ul
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methanol/ butanol/ chloroform (50/25/25) was added to keep the very long
chain acyl CoAs stable. The samples were run on LC-MS by Dr.
Padmamalini Srinivasan.

Analyze monitoring and quantification was

conducted with Analyst 1.5 Software from AB Sciex.

19

V. GC- MS Analysis of Fatty Acid Profile

Cells were resuspended in 1ml chloroform with 0.05% BHT and 2 ml
methanol with 0.05% BHT. 10 ug C17 standard was added to it and
incubated at room temperature with 30 min shaking. Cells were centrifuged
at 3000 rpm, 5 min at room temperature. Supernatant was transferred to
glass tubes and 1ml chloroform and 1.8ml water were added and the mixture
was vortexed.

Cells were centrifuged at 3000 rpm for 5min at room

temperature. The bottom phase was transferred to a small black capped glass
tube. It was dried under nitrogen stream and resuspended in 1ml chloroform.
This 1ml was split to 500ul for FAME and 500ul for GC-MS total lipid.
Both of them were dried under N2. The total lipid sample was kept in -20ºC.
The 500ul for FAME was resuspended in 250ul toluene and 500ul 1%
sulfuric acid in methanol. The sample was incubated at 50ºC overnight. The
1.25ml 5% NaCl was added and vortexed. The sample was extracted twice
using 1.25ml hexane. 1ml 2% potassium was added to the upper phase
combo and vortexed. The upper hexane phase was passed over 0.5g sodium
sulfate in glass packed pasture pipet and collected in a new tube. The sample
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was dried under N2 and resuspended in 1ml methyl acetate and transferred to
GC-MS vial for GC-MS running.
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VI. Quantitative Real-Time PCR

After 48 h of Tet induction, 1X107 cells were harvested using Qiagen total
RNA extraction kit. Then Bio-Rad cDNA synthesis kit was used for reverse
transcription step to obtain cDNA, which is used for the template in QPCR.
1 µg RNA/20 µl RT system was used. 1/10 dilution is used as the template
of PCR. For the standard curve preparation, genomic DNA is used as
template and the interested gene’s primers to do PCR.

After the

amplification, an agrose gel was run to analyze the samples. The bands
which are clear and at right sizes were cut. Gel extraction kit was used to
extract the PCR products. Nanodrop was used to see the concentration of the
gene fragments. Then the absolute number of each fragment according to the
concentration and the base pair numbers were calculated. Molecular copy
numbers/ µl=6.022 X 1023 X (Concentration of DNA (ng/µl) X 10-9)/ (base
pair X 650) 1011/ µl is usually kept for storage concentration. Then a series
of dilutions from 1010 to 103 will be done with PCR H2O.

For the QPCR, β-actin was used as the reference gene. Because the R2 is the
straightness of every gene’s standard curve, the R2s should be bigger than
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0.95. We used 10µl PCR reaction mix including 5µl of Syber Green mix, 1µl
cDNA template, 0.25µl each primer (10mM primer), 3.5µl ddH2O in 96
wells plate. Each sample was vortexed and spun down prior to PCR. The
PCR program was 95°C, 15 min; (95°C, 30s; 55°C, 30s; 68°C, 30s ) X 35
Cycles; melting curve 20min, 0.5°C increase from 55°C to 95°C per minute;
end 4°C. We keep the standard deviation lower than 0.2, R2 of each gene
higher than 0.95. The samples are triplicated.

The primers used are the following:
β-actin (reference gene)
Forward: 5’ CTGGGACGACATGGAGAAAA 3’
Reverse: 5’ AAGGAAGGCTGGAAGAGTGC 3’
hsFATP1(target gene)
Forward: 5’ CTGCCCTTAAATGAGGCAGTCT 3’
Reverse: 5’ AACAGCTTCAGAGGGCGAAG 3’
hsFATP4 (target gene)
Forward: 5’ TTCTGTGAAAGTCTCATGTCCAAGT 3’
Reverse: 5’ TCTCAGCCTGGGAACCAGAG 3’
hsPPAR-α (target gene)
Forward: 5- GCAAACTTGGACCTGAAC-3
Reverse: 5-CCCATTTCCATACGCTAC-3
hsPPAR-γ (target gene)
Forward: 5-CCAAGCTGCTCCAGAAAA-3
Reverse: 5-AGCGGGTGAAGACTCATGT-3
hsPLTP:
(target gene of PPARa)
Forward: 5-CATGCGGGATTCCTCACC-3
Reverse: 5-GAGGGGGCACTACAGGCTAT-3
hsPEPCK: (target gene of PPARg)
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Forward: 5-TGCTGGCTGGCCCGCACAGACCCC-3
Reverse: 5-GAGAAGGAGTTACAATCACCGTCT-3
hsHMGCS2: (target gene of PPARa)
Forward: 5-CAGATCCATGGAAAGCTTCCTGGG-3
Reverse: 5-ATTTACCAGCTAAGAGTGGGATCT-3
hsCD36: (target gene of PPARg)
Forward: 5-AGATGCAGCCTCATTTCCACCTTT-3
Reverse: 5-TTGACCTGCAAATATCAGAAGAAA-3

For the QPCR data analysis, we use software Excel to process the data we
collected from the thermo cycler to a bar figure (n=3). The copy number of
each gene / the copy number of β-actin = Y, the Y of empty vector was set
as 1 to compare the expression profile of these genes mentioned above.
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Chapter 3. Results and Discussion

I. The expression of human FATP1 can increase the expression of
human FATP4 at the protein level.

From our previous data, we used multiclonal antibodies to develop the
western blot of FATP1 and FATP4 and found put that FTAP4 can be seen in
both FATP1 overexpression and FATP4 overexpression cell lines. This can
be explained by two possibilities. One is the epitope of FATP1 and FATP4
in the multiclonal antibodies have some cross over. So, the FATP1
multiclonal antibody can bind with FATP4, but FATP4 antibody cannot
bind with FATP1. This epitope cross over can cause this western blot result
although these two genes don’t have any crosstalk between each other.
Another possibility is the human FATP1 really turn on the expression of
FATP4 on protein level.

For addressing this problem, we use the monoclonal antibody of each
protein. And the antigens sequences for each of them are checked to make
sure that they have no overlapping epitope from the vendor’s website. And
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for the better quantitative result comparable to QPCR assay for mRNA level,
we use Li-Cor system to execute our western blot.

From the western result, we can see there are still two bands in both FATP1
over expression and FATP4 over expression wells on the membrane antihsFATP4 (Figure 1) and only one band in FATP1 over expression well on
the membrane anti-hsFATP1 (Figure 2). This is consistent with our previous
preliminary data. We also find that the FATP4 band in FATP1 over
expression well is heavier than the band in FATP4 over expression itself.

This suggests that the expression of human FATP1 can increase the
expression of human FATP4 in protein level not because of the epitope cross
over. And the turned on FATP4 has a stronger expression level than the
construct overexpression. This gives us a clue that there are some
mechanisms involving in the crosstalk of these two proteins, at least on
protein expression level, the reason why FATP4 is turned on is unclear.
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II. FATP1 can turn on FATP4 not only at protein level but also at
mRNA level.

To check the crosstalk on mRNA level between these two genes,
quantitative PCR was used. We checked the human FATP1, human FATP4
mRNA level in empty vector (as control), FATP1 over expression cell line
and FATP4 over expression cell line and used β-actin as a reference gene.
The QPCR result is consistent with the western data (Figure 3, n=3).
hsFATP1 is over expressed in FATP1 over expression cell line and no
change in vector and FATP4 over expression cell line. hsFATP4 is over
expressed in FATP4 over expression cell line and almost 4 folds than vector
in FATP1 over expression cell line. This means hsFATP1 overexpression
really can turn on the mRNA level of hsFATP4. And this turn on effect is
robust, even higher than the construct overexpression itself.

For the expression of FATPs, they are regulated by the transcriptional
factors PPARs. If the FATP4 expression is up regulated, there should be
some reason to turn on the PPARs regulation of FATP4 specifically. Two
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possible approaches can achieve this up regulation. One is the expression of
PPAR is turned on. There are more PPARs to start the transcription. Another
potential way is the PPARs are more active than control because there is
more ligand binding to them.
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III. The effect of increasing FATP4 expression caused by FATP1
overexpression is through PPARα not through PPARγ, and it is
intermediated on post-transcription level not the transcription level of
PPAR γ.

PPARα and PPARγ mRNA levels and their target genes were evaluated by
QPCR. PEPCK is the specific target gene of PPARγ, HMGCS2 and PLTP
are the specific target genes of PPARα. Our idea is if the crosstalk is
mediated on transcriptional level, PPAR itself is over expressed. So, there
are more transcriptional factors to turn on the target genes expression. And if
this process is through post-transcription level, the expression of PPAR itself
will not change obviously, but the target genes are turned on.

From the QPCR result (n=3) (Figure 4.), neither of the PPAR expression is
turned on. This is the evidence that the effect is not caused by transcriptional
level. For the PPARα, target genes PLTP (phospholipid transfer protein) and
HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) are highly over
expressed than empty vector. But for the PPARγ, we find both FATP1 over
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expression

and

FATP4

over

expression

can

turn

on

PEPCK

(phosphoenolpyruvate carboxykinase), this cannot explain the one-way turn
on effect.

All fold changes of the genes we checked can be seen in Table I. FATP1 is
overexpressed in FATP1 OE cell line. FATP4 is 2 folds overexpressed in
FATP4 OE cell line but 4 folds in FATP1 OE cell line. This means FATP4
expression is elevated by the FTAP1 overexpression. Expressions of PPARα
and PPARγ keep the same in all of three cell lines. The target gene of
PPARγ, PEPCK is elevated by 2 times in both of FATP1 and FATP4
overexpression cell line. This may not the causal factor of FATP4
expression elevation. PLTP is 4 times of control group; HMGCS2 is more
than 40 times of control group. They are the target gene of PPARα. This
shows us that the elevation effect may cause the activation of PPARα and
the consequence of that is the expressions of these target genes are elevated.
CD36 keeps the same in each cell line. So, we can conclude that the increase
expression of FATP4 effect is through PPARα activation elevation not the
transcriptional level of it.

30

IV. Time-course fatty acid uptake assay of empty vector, FATP1 over
expression and FATP4 over expression.

To measure the initial uptake efficiency of different overexpression cell lines,
kinetic C1-BODIPY-C12 uptake assay is used. The patterns of fatty acid
transport were monitored using the live-cell, real-time method and the
fluorescently labeled fatty acid, 4, 4-difluoro-5-methyl-4-bora-3a, 4adiaza-sindacene-3-dodecanoic acid, C1-BODIPY-C12, in combination with the
quenching agent trypan blue (Figure 5).

From the C1-BODIPY-C12 initial uptake data (n=3, Figure 6 and 7), we
know that the over expression of FATP1 can uptake the C1-BODIPY-C12
more efficiently than FATP4 OE than empty vector. There should be some
reason that FATP1 over expression is effective than FATP4 over expression.

Our conclusion which is consistent with western and QPCR data is that
FATP1 can turn on FATP4.
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V. LC- /MS/MS Analysis of Fatty Acyl CoA Pool and GC-MS analysis
of the total fatty acids change of different 293 T-Rex over expression cell
lines.

After the 48 hours of Tet induction, we used LC-MS to see the CoA pool
change of different 293 T-Rex over expression cell lines. From the LC-MS
data, the acyl CoA profiles showed both C18:2-CoA and C20:4-CoA were
elevated in FATP1 expressing cell lines, perhaps indicating a relationship in
n-3 fatty acid activation including further downstream metabolism(n=3,
Figure 8). Likely effectors in this regulatory loop are arachidonic acid
metabolites, including prostaglandins.

And the GC-MS of lipids extraction of 293 T-Rex overexpression cell lines
after Tet induction also has been done to see the lipidome change of
different 293 T-Rex over expression cell lines. From the GC-MS data (n=3,
Figure 9), we cannot see the overexpression of these two transporters will
affect the fatty acids pool.
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But this can be explained by the method of our lipids sample extraction.
FAME was used the extract the total lipids inside of the cells. So, most
portion of this pool is at steady state, which can mask our data as minor
change. That’s why there is no significant change of fatty acids profile.
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Chapter 4. Summary

From the PQCR, Western and C1-BODIPY-C12 data collected from this
work, we found a phenomenon that FATP1 can turn up FATP4 expression,
but FATP4 cannot control FATP1.

And this regulation may be through a certain mechanism of posttranscriptional activation of PPARα because the up regulation of PPARα
target genes uniquely when the FATP1 is over expressed. The over
expression of FATP1 can uptake the C1-BODIPY-C12 more efficiently than
FATP4 than empty.

The LC/MS/MS for CoA pool and GC/MS for total fatty acids profile results
of FATP1 and FATP4 over expression cell lines also show some differences.
C18:2-CoA can be utilized to produce C20:4-CoA. So, increased C18:2CoA would cause C20:4-CoA increased. Prostaglandins were derived from
C20:4. There are some references also showing that arachidonic acid and its
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derivatives, exp. prostaglandin, can be the activators of PPAR. From this, we
may conclude our finding as increased expression of FATP1 elevated the
arachidonic acid CoA. But some references show that Acyl-CoA cannot be
the effector of PPARα. So, probably the downstream of C20:4-CoA can be
the effector causing the elevation of PPARα activation. C20:4-CoA can form
phospholipids, then C24:0 can be derived from phospholipids. And the
derivative of C24:0, prostaglandin, is likely to be the effector which
activates PPARα to upregulate the expression of FATP4.

For the future work, we should make sure the relationship between the
elevation of FATP expression and the activation of PPARα using a
luciferase PPAR reporter gene. Then we need to try to specify the group
which can activate this PPAR subtype, if it is arachidonic acid CoA or
prostaglandin.

From this work, we suggest a novel regulatory mechanism in fatty acid
metabolism that involves an enzymatic product, directly or downstream, of
FATP1, which functions as a PPARα effector. The eventual identification
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of this ligand may result in a target for eventual therapeutics directed to
control lipids homeostasis through PPARα.
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Figure 1. Western blot using anti-hsFATP1. Lane empty means the empty
vector as control. FATP1 OE is the cell line over expressing FATP1. Lane
FATP4 OE is the cell line over expressing FATP4.

M represents the

molecular weight markers. There is only one band in the lane of FATP1
overexpression indicating that FATP1 is overexpressed.
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Figure 2. Western blot using anti-hsFATP4. Lane empty means the empty
vector as control. FATP1 OE is the cell line over expressing FATP1. Lane
FATP4 OE is the cell line over expressing FATP4.

M represents the

molecular weight markers. Both lanes for FATP1OE and FATP4 OE are
showing the band for FATP4 overexpression.
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Fold change in expression
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FATP1 OE

FATP4 OE

Cell lines

Figure 3. mRNA levels of hsFATP1 and hsFATP4 in 3 cell lines. (n=3)
This is the QPCR data showing the fold change of interesting genes in
mRNA level relative to empty vector. The copy number of each gene / the
copy number of b-actin = Y, the Y of empty vector was set as one. Blue bars
present the FATP1 gene. Red bars present the FATP4 gene. The error bars
show the standard deviation. This data is consistent with western blot result.
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Figure 4. mRNA level of PPARα, PPARγ and their target genes in 3 cell
lines. (n=3) This is the QPCR data showing the fold change of interesting
genes in mRNA level relative to empty vector. The copy number of each
gene / the copy number of b-actin = Y, the Y of empty vector was set as 1.
Blue bars present the empty vector control cell line. Red bars present the
FATP1 over expression cell line. Green bars present the FATP4 over
expression cell line. The error bars show the standard deviation.
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Figure 5. The illustration of C1-BODIPY-C12 assay. The chemical
structure shows the molecular structure of C1-BODIPY-C12. Yellow zone
presents the cell membrane. Blue parts are the FATP as transporter of lipids.
Green dots are C1-BODIPY-C12 molecules. Trypan blue is used as the
quencher of C1-BODIPY-C12 outside of the cells. And the C1-BODIPYC12 gives out the signal to plate reader.
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Figure 6. C1-BODIPY-C12 assay of three interested cell lines. (n=3) This
figure shows the initial uptake rate of BODIPY by different cell lines at
different concentrations of BODIPY in medium. The data are present in
AFU/min/50,000 cells. Blue bars present the empty vector control cell line.
Red bars present the FATP1 over expression cell line. Green bars present the
FATP4 over expression cell line. The error bars show the standard deviation.
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Figure 7. Kinetic analysis of initial uptake rate using software PRISM.
Analysis
nalysis of the initial uptake rate of C1-BODIPY-C12 mimics the lipids
uptake by FATP as the enzyme process substrates. Round dots presents the
empty vector cell line. Triangle presents the FATP1 over expression cell line.
Square presents the FATP4 over expression cell line. X-axis
X
is the
concentration of C1-BODIPY
BODIPY-C12. Y-axis
axis is the AFU data per minute per
50,000 cells. For uptake rate, FATP1 OE > FATP4 OE > empty vector.

square is the amplification of some part of data. The error bars show the standard deviation.

line. Red bars present the FATP1 over expression cell line. Green bars present the FATP4 over expression cell line. The

the different CoA forms. Y-axis is the Mol percentage of different CoAs. Blue bars present the empty vector control cell

Figure 8. LC-MS of FA-CoAs extraction of 293 T-Rex Overexpression cell lines after Tet induction. (n=3) X-axis is
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standard deviation. The error bars show the standard deviation.

present the FATP1 over expression cell line. Green bars present the FATP4 over expression cell line. The error bars show the

different fatty acids. Y-axis is the Mol percentage of different FAs. Blue bars present the empty vector control cell line. Red bars

Figure 9. GC-MS of FAMEs extraction of 293 T-Rex Overexpression cell lines after Tet induction. (n=3) X-axis is the
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Cell lines
Genes tested

Empty vector
(Control set as 1.0)

FATP1 OE

FATP4 OE

FATP1
1.0±0.1
2.2±0.3 0.95±0.1
FATP4
1.0±0.15 3.8±0.4
2.0±0.2
1.0±0.1
1.1±0.1 1.05±0.2
PPARγ
PEPCK
1.0±0.1
1.9±0.2
2.0±0.1
PPARα 1.0±0.12 1.01±0.08 1.1±0.1
PLTP
1.0±0.1
4.3±0.6 1.02±0.1
HMGCS2 1.0±0.08 43.6±4.2 1.2±0.3
CD36
1.0±0.1 0.98±0.2 1.1±0.1

Table 1. The QPCR data of all of interested genes (n=3) This is the
overall QPCR data showing the fold change of interesting genes in mRNA
level relative to empty vector. The copy number of each gene/the copy
number of b-actin=Y. The Y of empty vector is set to one. ± shows the
deviation of data. The target genes of PPARα are overexpressed only in
FATP1 OE cell line, which gives a clue that the activation of PPARα may be
elevated.
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Cell Lines
Genes tested

Empty vector
(Control set as 1.0)

FATP1 OE

FATP4 OE

FATP2
FATP3
FATP5
FATP6
ACSL1
ACSL3
ACSL4
ACSL5
ACSL6

1.0±0.15
1.0±0.12
1.0±0.79
1.0±0.81
1.0±0.58
1.0±0.36
1.0±0.20
1.0±0.91
1.0±0.78

1.3±0.12
0.8±0.19
1.1±0.82
5.3±3.10
1.3±0.23
1.2±0.18
1.1±0.39
0.9±0.27
1.0±0.76

1.1±0.14
1.2±0.17
2.3±0.91
0.7±0.22
1.1±0.17
1.5±0.32
0.9±0.77
1.3±0.10
1.6±0.53

Table 2. The QPCR data of other tested genes (n=2, HPRT as the
reference gene) This is the overall QPCR data showing the fold change of
interesting genes in mRNA level relative to empty vector. The copy number
of each gene/the copy number of b-actin=Y. The Y of empty vector is set to
one. ± shows the deviation of data.
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